KRAS and familial pancreatic carcinoma: We discovered that, compared with the sensitive pancreatic cancer cell line HPAFII, both the intrinsically resistant cell line PANC1 and the acquired-resistance cell line HPAFIIR exhibited a high percentage of nucleus-localized YAP and TAZ, indicating the activation of YAP/TAZ in both intrinsically and acquired KRAS G12D inhibitor–resistant pancreatic cancer cells (Figure 9A and Supplemental Figure 12A).